Clinical Trials Browser

Active not recruiting × Everolimus × Head & Neck × Clear all

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT01141309 2025-07-22

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Diseases, Thyroid Neoplasms